Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Takeda Enters into Global Strategic Partnerships with Covance and Quintiles

By Pharmaceutical Processing | February 15, 2011

Takeda Pharmaceuticals International, Inc., a
wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, today
announced that its Pharmaceutical Development Division has entered into
strategic partnerships with Covance and Quintiles, two of the world’s largest
full-service contract research organizations.

Under terms of the agreements, Covance and Quintiles will
work in close partnership with Takeda to plan and execute global development programs
to support new compounds in all therapeutic areas, except oncology. Takeda will
have access to the clinical development capabilities and central laboratory
services of Covance and Quintiles, with each partner company providing
dedicated resources to support Takeda’s development pipeline. Takeda intends to
use a global program-level sourcing strategy to increase operational efficiency.

Through these relationships, Takeda will move toward a fully
virtual outsourcing model combining the expertise and capabilities of Takeda with
those of Covance and Quintiles to improve productivity and facilitate Takeda’s
global growth.

“Takeda is focused on growing its global drug
development footprint, especially in Asia,
while at the same time ensuring quality and increasing efficiency of our
operations,” said Robert Ahlbrandt, Ph.D., senior vice president, global
development operations for Takeda’s Pharmaceutical Development Division.
“Our new strategic partnerships with Covance and Quintiles will improve
the agility and productivity of our drug development activities, helping us to
deliver innovative new medicines to patients globally.”   

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE